Global Bioprocessing Equipment Market to Reach $152.2 Billion by 2035, Driven by Biologics Boom and Single-Use Technology Adoption
核心洞察
The global bioprocessing equipment market was valued at $48.1 billion in 2025 and is projected to reach $152.2 billion by 2035, expanding at a CAGR of 12.3%, according to Global Market Insights Inc.
Rising demand for biologics and biosimilars, rapid expansion of cell and gene therapy manufacturing, and growing adoption of single-use bioprocessing systems are key growth drivers.
North America held the largest market share at 38% in 2025, while Asia Pacific is projected to be the fastest-growing region with a CAGR of approximately 13.7%.
The global bioprocessing equipment market is on a steep growth trajectory, with its valuation expected to more than triple from $48.1 billion in 2025 to $152.2 billion by 2035, reflecting a compound annual growth rate (CAGR) of 12.3%, according to a comprehensive report published by Global Market Insights Inc. This expansion underscores the intensifying demand for advanced manufacturing technologies that support the production of biologics, biosimilars, vaccines, and cutting-edge cell and gene therapies.
The market's robust momentum is corroborated by a separate analysis from DelveInsight, which valued the broader biopharmaceutical processing equipment and consumables market at $52.1 billion in 2025, projecting growth to $116.4 billion by 2034 at a CAGR of approximately 9%. Both reports highlight the transformative role of single-use technologies, automation, and continuous bioprocessing in reshaping the biomanufacturing landscape.
Market Drivers: The Biologics Revolution and Single-Use Shift
The increasing commercialization of biologics and biosimilars stands as the foremost catalyst for market expansion. Monoclonal antibodies, recombinant proteins, vaccines, and cell-based therapies require sophisticated manufacturing systems to ensure high product quality and regulatory compliance. The monoclonal antibodies segment alone is projected to expand at an 11.9% CAGR, reaching $55.7 billion by 2035, driven by widespread use in treating cancers, autoimmune diseases, and chronic conditions.
Single-use bioprocessing systems have emerged as a pivotal force, progressively replacing traditional stainless-steel equipment. These disposable technologies—including bioreactor bags, tubing, connectors, and filtration systems—offer lower contamination risk, reduced cleaning requirements, faster turnaround times, and lower operational costs. "Single-use technologies are enabling manufacturers to lower infrastructure costs, shorten facility setup times, and reduce contamination risks, encouraging faster deployment of biomanufacturing capacity," the Global Market Insights report notes.
The rapid expansion of cell and gene therapy manufacturing is creating significant demand for specialized bioprocessing equipment. These therapies involve highly complex manufacturing processes requiring precise environmental control, advanced cell culture systems, and scalable production technologies. The cell and gene therapy segment, valued at $7 billion in 2025, is projected to grow at the fastest CAGR over the forecast period, with demand particularly strong for single-use systems, automated bioreactors, and process monitoring equipment capable of supporting small-batch, high-value production.
Regional Dynamics: North America Leads, Asia Pacific Surges
North America held the largest share of the global bioprocessing equipment market at 38% in 2025, with the U.S. market alone valued at $17.3 billion, up from $15.5 billion in 2024. The region's leadership is anchored by its well-established biopharmaceutical industry, robust manufacturing capabilities, and continuous investments in biologics research, development, and production. A mature supply chain infrastructure, highly skilled workforce, and strong focus on technological innovation further reinforce North America's dominant position.
Europe accounted for $14.5 billion in 2025, with countries such as Germany, the UK, Switzerland, France, and Ireland serving as important biopharmaceutical production hubs. The region is witnessing increased adoption of continuous manufacturing, automation technologies, and single-use equipment to enhance productivity and sustainability.
Asia Pacific is projected to be the fastest-growing region, with a CAGR of approximately 13.7% during the forecast period. Major economies including China, India, South Korea, and Japan are strengthening domestic biopharmaceutical production capabilities through supportive government policies, favorable regulatory frameworks, and competitive manufacturing costs. Leading manufacturers such as Samsung Biologics and WuXi AppTec continue to invest in large-scale biologics production facilities across the region, driving adoption of single-use technologies and next-generation bioprocessing solutions.
Competitive Landscape: Consolidation Among Top Players
The bioprocessing equipment industry exhibits a moderately consolidated competitive landscape. Danaher (搜索) led the market with over 29% share in 2025, focusing on strengthening its life sciences portfolio through continuous innovation, strategic acquisitions, and integrated bioprocessing solutions. The top five players—Danaher, Sartorius AG (搜索), Merck (搜索), Thermo Fisher Scientific (搜索), and Repligen Corporation—collectively held approximately 70% of the market.
Sartorius AG (搜索) emphasizes expansion of single-use technologies, cell culture solutions, and digital bioprocessing platforms. In February 2026, the company invested approximately EUR 442 million in expanding its bioprocess production capabilities, including facilities in Europe, with a focus on advanced filtration technologies and sustainable solutions.
Thermo Fisher Scientific (搜索) has been active on multiple fronts. In July 2025, the company acquired a manufacturing site from Sanofi to expand sterile fill-finish capacity. In May 2026, it introduced the Gibco CTS DynaXS Single Use Bioreactor, a purpose-built expansion platform designed to help cell therapy developers scale manufacturing with precise control, flexibility, and regulatory readiness.
Repligen Corporation made a significant strategic move in July 2026, entering into a definitive agreement to acquire BioLife Solutions, Inc. (搜索) for approximately $1.5 billion, aiming to strengthen its position as a key provider of critical technologies for biologics manufacturing.
Cytiva (搜索), part of Danaher (搜索), completed major capacity expansions including a 20% increase in membrane production at its Pensacola, Florida facility in June 2025, and significantly increased chromatography resin production in Uppsala, Sweden, as part of its $1.6 billion global investment program.
Technology Trends: Automation, AI, and Continuous Processing
Bioprocessing facilities are increasingly incorporating automation, artificial intelligence, and real-time monitoring solutions to improve process efficiency and consistency. Advanced control systems enable better data collection, predictive maintenance, and process optimization, helping manufacturers improve yields, reduce production errors, and enhance overall operational performance.
Continuous bioprocessing is gaining traction as companies seek higher productivity and cost efficiency. Unlike traditional batch processing, continuous manufacturing enables uninterrupted production, improves product consistency, reduces facility footprints, and supports faster scale-up.
The bioreactors segment held a leading market share valued at $13.3 billion in 2025, while filtration systems accounted for $11.3 billion and chromatography systems reached $8.7 billion. The upstream processing segment is projected to expand at a 12.1% CAGR to reach $87.5 billion by 2035, while downstream processing is expected to grow at a 12.6% CAGR to $64.7 billion.
Challenges and Opportunities
Despite strong growth prospects, the market faces notable challenges. High capital investment requirements for bioprocessing facilities continue to limit expansion plans, particularly for smaller biotechnology companies and startups. Stringent regulatory compliance requirements increase validation, documentation, and quality assurance burdens, resulting in longer implementation timelines and higher operational costs.
Opportunities lie in the increasing adoption of continuous bioprocessing technologies and growing demand for personalized medicine production, which will create demand for flexible, small-scale, and highly automated bioprocessing systems. The expanding role of contract manufacturing organizations (CMOs) and contract research organizations (CROs)—projected to grow at 13% through 2035—is also accelerating equipment procurement cycles as these service providers invest in flexible, multi-product manufacturing technologies.